US: Pharmaceuticals
featured
NEW YORK, April 5- A federal judge on Friday ordered the U.S. Food and Drug Administration to make "morning-after" emergency contraception pills available without a prescription to all girls of reproductive age and criticized the Obama administration for interfering with the process for political purposes.
» Read More
More
-
NEW DELHI, April 1- The Indian government hailed as "historic" a Supreme Court ruling on Monday against a plea by Swiss drugmaker Novartis AG to protect the patent on its drug Glivec.
-
MUMBAI, April 1- Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.
-
NEW DELHI/ MUMBAI, April 1- India's top court rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec, a move likely to boost the prospects of Indian pharmaceutical firms over their foreign rivals.
-
India's top court has dealt a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
-
NEW DELHI/ MUMBAI, April 1- India's top court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
-
NEW DELHI, April 1- India's highest court has dismissed Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms which are increasingly focusing on India to drive sales.
-
French drugmaker Sanofi SA said Friday that it's building a new medicine factory in Vietnam to supply drugs to that country and others in the region. Paris- based Sanofi said it plans to spend about $75 million to build the factory in Ho Chi Minh City.
-
WASHINGTON, March 28- The United States is striving to find an appropriate balance in Asia-Pacific free trade talks between providing strong patent and data protections for U.S. drug manufacturers and ensuring poor people have access to medicine, a U.S. trade negotiator said on Thursday.
-
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
-
A new study indicates that Obama's health care overhaul will result in a 32 percent claims cost increase which could translate into higher premiums for Americans.
-
*Supreme Court decision on Novartis patent due April 1. India's Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country.
-
*Supreme Court decision on Novartis patent due April 1. India's Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country.
-
BRUSSELS, March 27- Belgium- based drugmaker UCB. said it has raised the maximum 250 million euros it was aiming for by selling a retail bond on the Brussels stock exchange to help refinance its debt. The specialist in epilepsy drugs had aimed to raise between 100 million and 250 million euros through the sale.
-
FRANKFURT, March 27- German family-controlled drugmaker Merck KGaA said it replaced a 2 billion euro syndicated loan facility to secure long-term funding. The loan, underwritten by a group of international banks, runs for five years with extension options for seven years.
-
MUMBAI, March 27- Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling next week that could have broad consequences for their ability to sell lucrative patented medicines in the country.
-
MUMBAI, March 27- Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling next week that could have broad consequences for their ability to sell lucrative patented medicines in the country.
-
*Research sheds light on breast, prostate, ovarian cancer. LONDON, March 27- New research has nearly doubled the number of genetic variations implicated in breast, prostate and ovarian cancer, offering fresh avenues for screening at-risk patients and, potentially, developing better drugs.
-
*Research sheds light on breast, prostate, ovarian cancer. LONDON, March 27- New research has nearly doubled the number of genetic variations implicated in breast, prostate and ovarian cancer, offering fresh avenues for screening at-risk patients and, potentially, developing better drugs.
-
GLEN ALLEN, Va.-- Star Scientific Inc. said Tuesday that it plans to vigorously contest allegations in a lawsuit filed against the dietary supplements and cosmetics company. A lawsuit was filed in the U.S. District Court for the Eastern District of Virginia on behalf of people who bought Star Scientific shares between October 31, 2011 and March 18, 2013.
-
SINGAPORE, March 26- Singapore's Economic Development Board on Tuesday released the following industrial production data for February:. -The drop in February industrial production was partly due to the Lunar New Year holidays that began on Feb. 10 this year.